X4 Pharmaceuticals, Inc — Director's Dealing 2021

Aug 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: X4 Pharmaceuticals, Inc (XFOR)
CIK: 0001501697
Period of Report: 2021-08-17

Reporting Person: Meisner Derek M (General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-17	Common Stock	S	8332	$5.10	Disposed	72730	Direct

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $4.98 to $5.35, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: Represents unvested restricted stock units.